ClinicalTrials.gg
CompletedNCT01763645Updated Jan 11, 2024Results posted

A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer

A Phase 3 interventional study of Bevacizumab and Paclitaxel in Non-small Cell Lung Cancer, sponsored by Biocad. Completed at 44 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-11.

Sponsored by Biocad · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 15 under way, 3 of them phase 3. Bevacizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
26th of 149
353 · median 56
Started
2012
with 5 others
Phase 3
29 of 150
1 open now
Registered
89th of 150
by date

Among the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, this one is the 26th largest by enrollment of the 149 interventional ones that give a count, is one of 6 that started in 2012, is one of 29 in phase 3, and was the 89th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

BCD-021-02 is a double-blind randomized clinical trial comparing efficacy of BCD-021 (INN: bevacizumab) and paclitaxel + carboplatin to Avastin and paclitaxel + carboplatin in inoperable or advanced non-squamous NSCLC patients with pharmacokinetics substudy. The purpose of the study is to demonstrate the non-inferiority of efficacy and safety of BCD-021 compared to Avastin. Also study includes pharmacokinetics assessment.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • NSCLC
  • bevacizumab
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written ;
  • Newly diagnosed or cytologically confirmed NSCLC excluding squamous NSCLC (mixed cancer types should be classified according to the prevalent cell type);
  • IIIb or IV stage of NSCLC (TNM classification version 6);
  • Age ≥ 18 years and age ≤ 75 years (both inclusive);
  • (ECOG) performance status 0, 1 or 2, (not declining within 2 weeks prior to the first dose of product);
  • - 12 weeks or more from the moment of randomization;
  • Presence of at least 1 measurable tumour with a size not less than 1 cm (revealed with CT slice thickness not more than 5 mm), as defined by modified (RECIST) criteria (specifically, no ascites, pleural, or pericardial effusions, osteoblastic bone , or carcinomatous lymphangitis of the lung as only lesion;
  • Patients should be able to follow the Protocol procedures (according to Investigator's assessment);
  • Patients must implement reliable measures during all the study treatment, starting 4 weeks prior to the administration of the first dose of investigational product until 6 months after the last dose of investigational product. This requirement does not apply to participants who have undergone surgical sterilization, or patients who are (documented) for the past 2 years. Reliable contraceptive measures include two methods of contraception, including one barrier method

Exclusion criteria

Exclusion Criteria:

  • Squamous NSCLC;
  • Proven coagulopathy, hemorrhage in the past including nasal hemorrhage;
  • \<1500/mm3;
  • \<100 000/mm3;
  • \< 90 g/L;
  • Creatinine level ≥1.5 mg/dL;
  • level ≥1.5 × (ULN);
  • Aspartate-aminotransferase() and alanine-aminotransferase (ALT) levels ≥2.5 × ULN (≥5 × ULN for patients with liver );
  • Alkaline phosphatase level ≥5 × ULN;
  • Current therapeutic anticoagulation treatment, aspirin (more than 325 mg/day), nonsteroidal anti-inflammatory drugs, antiplatelet agents or protracted treatment with these drugs less than 1 month before entering the study;
  • Uncontrolled hypertension comprising all cases of arterial hypertension when no decrease in blood pressure could be achieved despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medical correction methods (low salt diet, physical exercise);
  • Any previous anticancer therapy (chemotherapy, radiation therapy , surgery etc.) of metastatic NSCLC;
  • Radiation or hormone therapy within 21 days prior to randomization;
  • Major surgery 28 days before inclusion into the study;
  • Previous antiangiogenic therapy;
  • to taxanes, platinum agents, recombinant murine proteins, contrast agents, premedication agents specified by Protocol (dexamethasone, diphenhydramine, ranitidine) or of products;
  • NSCLC metastases in central nervous system excluding metastases non-progressing without glucocorticosteroids within 4 weeks before inclusion into the trial;
  • Cardiovascular system pathology (CHF stage III-IV according to (NYHA) classification);
  • Pregnancy or lactation;
  • Conditions limiting patient's adherence to Protocol requirements (dementia, neurologic or psychiatric disorders, drug addiction, alcoholism and others);
  • Stage II-IV neuropathy according to (CTCAE) v.4.0;
  • Simultaneous participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial;
  • Any other concomitant cancer revealed within 5 years prior to screening, except curatively treated intraductal carcinoma in situ, curatively treated cervical carcinoma in situ or curatively treated basal cell or squamous cell carcinoma;
  • Acute or active chronic infections;
  • virus, virus, , or syphilis infections;
  • Obstacles in intravenous administration of study drugs
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    BCD-021 (CISC BIOCAD)

    BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.

    Drug: Bevacizumab · Drug: Paclitaxel · Drug: Carboplatin

  • Active comparator
    Avastin (F. Hoffmann-La Roche Ltd)

    In this arm patients will receive 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.

    Drug: Bevacizumab · Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).

    Also known as: Avastin, BCD-021

  • Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)

    Also known as: Taxacad

  • Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Day 127

  2. Area Under the Curve After the First Test Drug Administration

    primary outcome measure for pharmacokinetics (PK) substudy

    Time frame: up to Day 22, after the first bevacizumab administration (time points for blood samples: 0 h 1.5 h, 3 h, 4.5 h, 6 h, 24 h, 96 h, 168 h, 336 h and 504 h)

Secondary outcomes

  1. Complete Response Rate

    secondary outcome measure for efficacy evaluation

    Time frame: Day 127

  2. Partial Response Rate

    secondary outcome measure for efficacy evaluation

    Time frame: Day 127

  3. Stabilization Rate

    secondary outcome measure for efficacy evaluation

    Time frame: Day 127

  4. Progression Rate

    secondary outcome measure for efficacy evaluation

    Time frame: Day 127

  5. Occurrence of Anti-bevacizumab Antibodies

    Secondary outcome measure for immunogenicity assessment

    Time frame: Day 1 (before the drug administration), Day 15, 64 and 127

07

Results

Posted Oct 24, 2016

Participant flow

Participant flow — Overall Study
MilestoneBCD-021 (CISC BIOCAD)Avastin (F. Hoffmann-La Roche Ltd)
Started211142
Received at least 1 dose of study drug206137
Completed8756
Not completed12486

Outcome measures

PrimaryOverall Response Rate

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Day 127
Reported as:
Number · percentage of participans
Overall Response Rate
percentage of participansBCD-021 (CISC BIOCAD)Avastin (F. Hoffmann-La Roche Ltd)
Overall Response Rate34.6333.82
PrimaryArea Under the Curve After the First Test Drug Administration

primary outcome measure for pharmacokinetics (PK) substudy

Time frame:
up to Day 22, after the first bevacizumab administration (time points for blood samples: 0 h 1.5 h, 3 h, 4.5 h, 6 h, 24 h, 96 h, 168 h, 336 h and 504 h)
Reported as:
Median · (ng/ml)*hour
Area Under the Curve After the First Test Drug Administration
(ng/ml)*hourBCD-021 (CISC BIOCAD)Avastin (F. Hoffmann-La Roche Ltd)
Area Under the Curve After the First Test Drug Administration26951463 (6114172.35 to 68355846)23970112.875 (8216733.75 to 80859445.5)
SecondaryComplete Response Rate

secondary outcome measure for efficacy evaluation

Time frame:
Day 127
Reported as:
Number · percentage of patients
Complete Response Rate
percentage of patientsBCD-021 (CISC BIOCAD)Avastin (F. Hoffmann-La Roche Ltd)
Complete Response Rate1.85 (0.33 to 9.77)1.79 (0.32 to 9.45)
SecondaryPartial Response Rate

secondary outcome measure for efficacy evaluation

Time frame:
Day 127
Reported as:
Number · percentage of patients
Partial Response Rate
percentage of patientsBCD-021 (CISC BIOCAD)Avastin (F. Hoffmann-La Roche Ltd)
Partial Response Rate40.74 (28.68 to 54.03)37.50 (26.01 to 50.59)
SecondaryStabilization Rate

secondary outcome measure for efficacy evaluation

Time frame:
Day 127
Reported as:
Number · percentage of patients
Stabilization Rate
percentage of patientsBCD-021 (CISC BIOCAD)Avastin (F. Hoffmann-La Roche Ltd)
Stabilization Rate51.85 (38.85 to 64.60)51.79 (39.01 to 64.34)
SecondaryProgression Rate

secondary outcome measure for efficacy evaluation

Time frame:
Day 127
Reported as:
Number · percentage of patients
Progression Rate
percentage of patientsBCD-021 (CISC BIOCAD)Avastin (F. Hoffmann-La Roche Ltd)
Progression Rate5.56 (1.91 to 15.11)8.93 (3.88 to 19.26)
SecondaryOccurrence of Anti-bevacizumab Antibodies

Secondary outcome measure for immunogenicity assessment

Time frame:
Day 1 (before the drug administration), Day 15, 64 and 127
Reported as:
Number · percentage of patients
Occurrence of Anti-bevacizumab Antibodies
percentage of patientsBCD-021 (CISC BIOCAD)Avastin (F. Hoffmann-La Roche Ltd)
Occurrence of Anti-bevacizumab Antibodies1.471.52

Adverse events

Collected over 6 therapy cycles. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BCD-021 (CISC BIOCAD)14/206 (6.8%)36/206 (17.5%)206/206 (100%)
Avastin (F. Hoffmann-La Roche Ltd)8/137 (5.8%)20/137 (14.6%)137/137 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventBCD-021 (CISC BIOCAD)Avastin (F. Hoffmann-La Roche Ltd)
Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders5/2063/137
DeathGeneral disorders3/2062/137
GastroenteritisInfections and infestations3/2060/137
Disease progressionGeneral disorders3/2061/137
NeutropeniaBlood and lymphatic system disorders2/2061/137
ProctitisGastrointestinal disorders2/2061/137
Pneumothorax spontaneousRespiratory, thoracic and mediastinal disorders0/2061/137
DyspnoeaRespiratory, thoracic and mediastinal disorders0/2061/137
Metastases to meningesNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2061/137
Febrile neutropeniaBlood and lymphatic system disorders1/2061/137
Most frequent other events
Showing 10 of 33
Most frequent other events
EventBCD-021 (CISC BIOCAD)Avastin (F. Hoffmann-La Roche Ltd)
AnaemiaBlood and lymphatic system disorders104/20678/137
ThrombocytopeniaBlood and lymphatic system disorders60/20642/137
LeukopeniaBlood and lymphatic system disorders42/20639/137
NeutropeniaBlood and lymphatic system disorders45/20637/137
AlopeciaSkin and subcutaneous tissue disorders53/20627/137
HyperglycaemiaMetabolism and nutrition disorders39/20634/137
NeutrophiliaBlood and lymphatic system disorders19/20627/137
LeukocytosisBlood and lymphatic system disorders25/20625/137
Blood lactate dehydrogenase increasedInvestigations25/20620/137
LymphopeniaBlood and lymphatic system disorders23/20618/137

Baseline characteristics

Patients who received at least 1 dose of the study drug

Age, Continuous
Age, Continuous(years)BCD-021 (CISC BIOCAD)Avastin (F. Hoffmann-La Roche Ltd)Total
Mean57.79 ± 8.8858.67 ± 8.3358.23 ± 8.61
Sex: Female, Male
Sex: Female, Male(Participants)BCD-021 (CISC BIOCAD)Avastin (F. Hoffmann-La Roche Ltd)Total
Female14288230
Male6348111
08

Study locations

44 sites
  • Brest Regional Clinical Dispensary
    Brest, Belarus
  • Gomel Regional Clinical Oncology Dispensary
    Gomel, Belarus
  • Grodno Regional Clinical Hospital
    Grodno, Belarus
  • Vitebsk Regional Clinical Oncology Dispensary
    Vitebsk, Belarus
  • HCG Bangalore Institute of Oncology
    Bangalore, 560027, India
  • M.S.Ramaiah Memorial Hospital
    Bangalore, 560054, India
  • Narayana Hrudayalaya Hospitals
    Bangalore, 560099, India
  • Arkhangelsk District Clinical Oncology Dispensary
    Arkhangelsk, 163045, Russian Federation
  • Non-governmental Healthcare Institution "Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways"
    Chelyabinsk, 454000, Russian Federation
  • State-financed Health Institution "Chelyabinsk Region Clinical Oncology Dispansary"
    Chelyabinsk, Russian Federation
  • State Healthcare Facility "Kursk Regional Oncology Dispensary"
    Kursk, 305035, Russian Federation
  • State Health Institution of Moscow "Moscow City Oncology Hospital #62 of Moscow Board of Health"
    Moscow Region, 143423, Russian Federation
  • Institution of Russian Academy of Medical Sciences "Russian Cancer Research Center named after N.N. Blokhin"
    Moscow, 115478, Russian Federation
  • Federal State Institution "Moscow Institute of Cancer Research named after P.A. Hertsen" Ministry of Health of Russian Federation
    Moscow, 194044, Russian Federation
  • Murmansk Regional Oncology Dispensary
    Murmansk, 183047, Russian Federation
  • Nizhny Novgorod Region State Budgetary Healthcare Facility "Clinical Diagnostics Center"
    Nizhny Novgorod, 603006, Russian Federation
  • State Healthcare Facility "Nizhny Novgorod Regional Oncology Dispensary"
    Nizhny Novgorod, Russian Federation
  • City Clinical Hospital №1
    Novosibirsk, 630047, Russian Federation
  • Regional State Health Institution "Orlov Oncology Dispansary"
    Orel, 302020, Russian Federation
  • State Health Institution "Region Oncology Dispansary"
    Penza, 440071, Russian Federation
  • Perm Region Oncology Dispensary
    Perm, 614066, Russian Federation
  • Federal Government Budgetary Institution "Rostov Institute of Cancer Research" of Ministry of Health of Russian Federation
    Rostov-on-Don, 314019, Russian Federation
  • Saint Petersburg City Clinical Oncology Center
    Saint Petersburg, 197022, Russian Federation
  • State-financed Health Institution "Samara Region Clinical Oncology Dispansary"
    Samara, 443031, Russian Federation
  • Oncology Dispensary 2
    Sochi, 354057, Russian Federation
  • St. Petersburg State Medical University n.a. I. P. Pavlov
    St. Petersburg, 197022, Russian Federation
  • St. Petersburg Research and Practice Center for Secondary Care in Oncology
    St. Petersburg, 197758, Russian Federation
  • N.N.Petrov Oncology Research Center
    St.Petersburg, 197758, Russian Federation
  • Military Medical Academy named after S.M. Kirov
    St.Petersburg, Russian Federation
  • Russian scientific center of radiology and surgery technologies
    St.Petersburg, Russian Federation
  • State-financed Health Institution "Stavropol Region Clinical Oncology Dispansary"
    Stavropol, 355047, Russian Federation
  • Volgograd District Oncology Dispensary №1
    Volgograd, 400138, Russian Federation
  • Volgograd Regional Oncology Dispensary №3
    Volgograd, 404130, Russian Federation
  • State Health Institution "Voronezh Region Clinical Oncology Dispansary"
    Voronezh, 394000, Russian Federation
  • Donetsk City Oncology Dispensary
    Donetsk, Ukraine
  • Donetsk Regional Antitumor Center
    Donetsk, Ukraine
  • Kharkiv Regional Clinical Oncology Center
    Kharkiv, Ukraine
  • Kryvyi Rih Oncology Dispensary
    Kryvyi Rih, Ukraine
  • Lviv State Regional Cancer Diagnostic and Treatment Center
    Lviv, Ukraine
  • City Hospital № 2
    Makiivka, Ukraine
  • Poltava Regional Clinical Oncology Dispensary
    Poltava, Ukraine
  • Zakarpatskyi Clinical Oncology Dispensary
    Uzhhorod, Ukraine
  • Vinnytsia Regional Clinical Oncology Dispensary
    Vinnytsia, Ukraine
  • Zaporizhia Regional Clinical Oncology Dispensary
    Zaporizhia, Ukraine
09

References and documents

Publications

  • Stroyakovskiy DL, Fadeeva NV, Matrosova MP, Shelepen KG, Adamchuk GA, Roy B, Nagarkar R, Kalloli M, Zhuravleva D, Voevodin GD, Shustova MS, Kryukov F. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab. BMC Cancer. 2022 Feb 1;22(1):129. doi: 10.1186/s12885-022-09243-7. PubMed 35105329 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Nov 2014, 25 months.

Results were first posted in Oct 2016, 1 year 11 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 25 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2012
First posted
Jan 9, 2013
StartActual
Oct 2012
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Oct 24, 2016
Last update
Jan 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01763645
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Jan 9, 2013
Start date
Oct 2012
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Oct 24, 2016
Last update
Jan 11, 2024

Study contacts

Yulia Linkova, MD, PhD
study director · Director of Clinical Development Department, BIOCAD

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Paclitaxel · Carboplatin

Start the discussion